| Document |
Document Title |
|
WO/2002/085359A1 |
The present invention provides an agent for topical ophthalmic treatment of a human for ocular inflammatory diseases, containing a tricyclo compound as shown by the general formula (I) or its pharmaceutically acceptable salt as the activ...
|
|
WO/2002/086142A1 |
It is intended to provide a novel process for producing soyasapogenol B which is useful as a drug or a material for producing drugs. Sophoradiol employed as a starting material is treated with a hydroxylase originating in a plant to ther...
|
|
WO/2002/085395A1 |
This invention provides a composition comprising Paeoniflorin, Albiflorin, Oxypaeoniflorin, and Benzoylpaeomiflorin. This invention also provides a pharmaceutical composition comprising an effective amount of Paeoniflorin, Albiflorin, Wx...
|
|
WO/2002/086503A1 |
It is intended to provide novel lipopolysaccharide adsorbents (bacteriotoxin adsorbents) which can be easily synthesized and modified into various analogous structures and are usable in adsorbing various lipopolysaccharides and a method ...
|
|
WO/2002/085403A1 |
The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism Streptomyces hygroscopicus.
|
|
WO2001052746A9 |
Dye-peptide conjugates useful for diagnostic imaging and therapy are disclosed. The dye-peptide conjugates include several cyanine dyes with a variety of bis- and tetrakis(carboxylic acid) homologues. The small size of the compounds allo...
|
|
WO/2002/083066A2 |
Crystalline complexes are obtained from a 1:1 or 2:1 mixtures of either the (D) or (L) enantiomer of natural amino acids and compounds of formula (I) wherein R¿1?, R¿2? and R¿2a? are independently hydrogen, OH, OR¿5?, alkyl, -OCHF?2Â...
|
|
WO/2002/080936A1 |
Combination therapy comprising PPAR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.
|
|
WO/2002/081480A1 |
The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.
|
|
WO/2002/081466A1 |
The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatmen...
|
|
WO/2002/081491A2 |
Genistein derivatives of Formula (1), wherein R�1? and R�2? are the same or different and independently represent hydrogen atom, alkyl, aryl, alkyloaryl, alkylcarbonyl, arylcarbonyl, while each of the above mentioned groups may be su...
|
|
WO/2002/081483A2 |
The present invention provides compounds with activity as inhibitors of acyl glucosaminylinositol amidases with amidase activity against S-conjugate amides, particularly mycothiol-derived S-conjugate amides. Certain of the invention comp...
|
|
WO/2002/079213A1 |
The present invention is directed to the process for the preparation of 2'-deoxy-2'-halo-$g(b)-L-arabinofuranosyl nucleosides, and in particular, 2'-deoxy-2'-fluoro-$g(b)-L-arabinofuranosyl thymine (L-FMAU), from L-arabinose, which is co...
|
|
WO/2002/078597A2 |
Orally nonabsorbed or poorly absorbed drugs may be converted to orally absorbed prodrug derivatives by derivatization of free functional groups selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to m...
|
|
WO/2002/079150A2 |
The present invention provides combinatorial methods for rapidly generating a diverse library of glycorandomized structures, comprising incubating one or more aglycons and a pool of NDP-sugars in the presence of a glycosyltransferase. Th...
|
|
WO/2002/076402A2 |
The invention provides conjugates of fatty amines and pharmaceutical agents useful in treating cancers, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparations of the fatty amine-pharmaceuti...
|
|
WO/2002/077255A1 |
The present invention relates to fluoro sugar and other sugar derivatives of indolopyrrolocarbazoles, their salts and hydrates, which exhibit selective topoisomerase I (topo I) activity, are useful in inhibiting the proliferation of tumo...
|
|
WO/2002/076448A1 |
A molecular conjugates is provided having Formula (I) wherin n is the conjugation number, P is a moiety of a carrier molecule such as a protein, R¿1? is a moiety of a biologically active molecule or its analogs, derivatives, salts or se...
|
|
WO/2002/077004A1 |
Macrolide compounds produced by synthetic modification of factors produced by NRRL 30141 have insecticidal and acaricidal activity and are useful intermediates for preparing additional insecticidal and acaricidal compounds.
|
|
WO/2002/074737A2 |
A process for the preparation of 2-hydroxymethyl-pyrrolidine-3,4-diols of the formulae comprising the steps of a) biooxidation of N-protected aminotetraols of the formula b) deprotection of the corresponding N-protected 5-amino-5-deoxy-p...
|
|
WO/2002/072110A1 |
The invention relates to novel active substances (caloporoside derivatives), which are formed by the microorganism Gloeoporus dichrous (Fr.:Fr.) Bres. ST001714, DSM 13784 during fermentation. The invention also relates to methods for pro...
|
|
WO/2002/072593A2 |
The present invention relates to alkylated C-sugars which are now carbohydrate derivatives based on the 'C-Sugar' platform. These alkylated C-sugars are converted from hydrophilic, hydrogen-bonded saccharide derivatives and are very stab...
|
|
WO/2002/069704A2 |
This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containinga) a termiticide selected such that the termiticide causes death to about 5...
|
|
WO2001040232A9 |
Novel C-13<2>-COXR1, C-17<2>-COXR2 and C-13<2>-COXR1, C-17<2>-COXR1 derivatives of chlorophyll and bacteriochlorophyll compounds are provided wherein X is O, S or N and R1 and R2 , the same or different, may be an optionally substituted ...
|
|
WO/2002/068439A1 |
Glucopyranosyloxypyrazole derivatives represented by the following general formula (I) expressing an excellent human SGLT2 activity inhibitory effect and thus being useful as preventives or remedies for diseases caused by hyperglycemia s...
|
|
WO/2002/065989A2 |
The present invention provides a method of treating lysomal storage diseases such as Hurler syndrome and Batten disease in individuals in need of such treatment, comprising the step of administering to said individuals a therapeutically ...
|
|
WO/2002/064606A1 |
Glucopyranosyloxybenzylbenzene derivatives represented by the following general formula (I) and pharmacologically acceptable salts thereof which are useful as preventives or remedies for diseases caused by hyperglycemia such as diabetes,...
|
|
WO2000026223A9 |
The present invention discloses new and novel substituted anthracyclines having a three ring system or other DNA binding moities. These congeners show high activity in vitro against several tumor cell lines. The invention also describes ...
|
|
WO/2002/064605A2 |
This invention provides $g(b)-D-Glucuronidase substrates of formula (I) wherein R¿1?, R¿2?, and R¿7? - R¿12? are independently selected from the group consisting of: hydrogen, fluorine, chlorine, bromine, iodine, alkyl, hydroxyl, alk...
|
|
WO/2002/064556A2 |
A complex carbohydrate array is provided,which including a plurality of addressable complex carbohydrate structures.
|
|
WO2002032915B1 |
The present invention provides a monosaccharide compound of general formula I as shown in the specification. The invention also provides processes for the preparation of the compound of formula I and methods of screening for antibacteria...
|
|
WO/2002/062810A2 |
Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLe?X¿) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in prep...
|
|
WO/2002/062812A1 |
The present invention relates to a process for isolating flax lignans. Specifically this invention provides a process for isolating and purifying secoisolariciresinol diglycoside (SDG) from crushed flaxseed by means of supercritical carb...
|
|
WO/2002/060911A2 |
A C-glucosyl ether lipid of the following formula (I): wherein R¿1? is a C¿12?-C¿20? alkyl or C¿12?-C¿20? alkenyl; R¿2? is a C¿1?-C¿3? alkyl or C¿3? cycloalkyl; and X is anitrogen-containing group.
|
|
WO/2002/057281A2 |
The present invention provides aminoglycosides and pharmaceutical compositions that include the aminoglycosides. The aminogylcosides are useful to treat or prevent infectious diseases (e.g., bacterial infections) in a mammal (e.g., human).
|
|
WO/2002/057285A1 |
A fullerene derivative represented by the formula (I): (I) wherein A represents a residue of a monosaccharide or disaccharide, Alk represents a lower alkylene group, a group represented by the formula (X): (X) represents a fullerene resi...
|
|
WO/2002/055490A2 |
A metabolic controlled fermentation process has been developed for the production of carbamoyl tobramycin by the application of different Streptocmyces tenebrarius strains in submerged cultures at a temperature within about 37-41°C on a...
|
|
WO/2002/051862A2 |
The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to specific carbohydrate moieties via preferred linking units which can be selectively cleaved by enzymes such as metallo matrixprotea...
|
|
WO/2002/051779A2 |
The invention relates to a method for producing alcohols by catalytically hydrogenating carbonyl compounds with hydrogen or with gases that contain hydrogen in the presence of a hydrogenation catalyst of the Raney type, whereby the catal...
|
|
WO2000052018A9 |
In certain embodiments, the present invention relates to versatile linkers for tethering a molecule to a solid support, e.g. for tethering a monomer, oligomer or polymer to a solid support, which are stable to a wide range of reaction co...
|
|
WO/2002/050090A1 |
Hypocholesterolemic sugar-substituted 2-azetidinone compounds of the formula: are disclosed, as well as a method of lowering cholesterol by administering said compounds, pharmaceutical compositions containing them, and the combination of...
|
|
WO/2002/048163A2 |
Disclosed are novel synthetic processes for the preparation of $g(a)Gal(1$m(7)4) $g(b)Gal(1$m(7)4)Glc-OR trisaccharides.
|
|
WO/2002/048331A2 |
The present invention provides mutant nucleotidylyltransferases, such as E¿p?, having altered substrate specificity; methods for their production; and methods of producing nucleotide sugars, which utilize these nucleotidylyltransferases...
|
|
WO/2002/043678A2 |
The invention relates to a method for the enzymatic fixation of derivatised carbohydrates to fibrous, in particular keratinous materials, such as hair or wool, to a multi-component system comprising at least one carbohydrate derivative a...
|
|
WO/2002/044191A2 |
Methods for treating, preventing, or inhibiting diseases and disorders associated with inflammation, cell-proliferation, and pain comprising the administration of a compound having the structural formula (I) wherein R¿1? is a hydrogen, ...
|
|
WO/2002/044192A1 |
Glucopyranosyloxybenzylbenzene derivatives represented by the following general formula (I), which are useful as preventives or remedies for diseases caused by hyperglycemia (for example, diabetes, diabetic complications, obesity) becaus...
|
|
WO/2002/044190A2 |
Disclosed are novel synthetic processes for preparation of the trisaccharide $g(a)Gal(1$m(7)3)$g(b)Gal(1$m(7)4)Glc-OR compounds.
|
|
WO/2002/042270A1 |
Compounds having an anticoagulant effect based on the inhibition of activated blood coagulation factor X and being useful as anticoagulants or preventives/remedies for diseases induced by thrombosis or embolism. Namely, compounds such as...
|
|
WO2001042179A9 |
Compounds which mimic the chemical and/or biological activity of discodermolide are provided and intermediates useful in their preparation.
|
|
WO/2002/039832A1 |
The present invention relates to the use of lactitol in the preparation of a nutritional preparation for improving intestinal microflora, in particular in an amount of 5 to 15 g lactitol per daily dose. The nutritional preparation can be...
|
